Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497743 | 0.78 | TSHR (0.32) | — | |
| SCHEMBL3936601 | 0.75 | P2RX4 (0.32) | — | |
| SCHEMBL498403 | 0.74 | — | — | |
| SCHEMBL2334377 | 0.70 | TSHR (0.33) | — | |
| SCHEMBL4721437 | 0.70 | FFAR3 (0.33) | — | |
| SCHEMBL497744 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL5207482 | 0.70 | — | — | |
| SCHEMBL329195 | 0.69 | TSHR (0.36) | — | |
| Hydrochloric Acid SCHEMBL329196 | 0.69 | FFAR3 (0.32) | — | |
| SCHEMBL4234787 | 0.69 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | LAP3 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.